Efficient anticancer properties of ashwagandha extracted phytochemicals for lower protein expression on U-251 and clove extracts on LN-229 GBM cell lines

Title : Efficient anticancer properties of ashwagandha extracted phytochemicals for lower protein expression on U-251 and clove extracts on LN-229 GBM cell lines

Abstract:

Glioblastoma Multiforme G IV primary malignant Brain tumor medications such as Radiation, Surgery, Gene therapy, Chemotherapy and Ayurveda which are not very much successful with clinical studies. However, the trials are being made towards the various cancers’ successful treatment with less side effects. Hence natural phytochemicals extract of Ashwagandha (Withania somnifera) Soya bean (Glycine max) and Clove (Syzygium aromaticum) are also considered for cancer therapeutics having much side effects on Human brain cells and organs.

The Phytochemicals treated GBM cell lines U251 and LN229 subjected for MTT assay, SDS gel electrophoresis, Protein content determination by  Lowry and Bradford assays.

The Ashwagandha extracted phytochemicals such as Alkaloids, tannins, saponins, phlobatannins, Flavonoids, Terpenoids were determined. Ashwagandha phytochemicals extract treated U251 cells showed IC50-1.1 µg/100 µl and 83.95% cell death for the same concentration.

The LN 229 Cell viability reduced to 40% with clove phytochemicals and cinnamaldehyde.

The protein content reduced to 118.68µg/ml for 138µl/ml Ashwagandha phytochemicals as compared to control protein 257.25 µg/ml. Whereas, less protein band intensity displayed for phytochemicals of Ashwagandha, treated U251 cells and less protein expressed for cinnamaldehyde and clove extract phytochemicals treated LN229 cells respectively when compared to  their control.

Therefore, GBM U251 and LN 229 cells treated with Phytochemicals of Ashwagandha and clove showed reduction in protein expression directly depicts tumor cell death that acts as anticancer drug conjugate.

Key words: GBM Cells; U 251; LN229; Phytochemicals; Protein expression; Tumor cell death.

Biography:

Prabha Muddobalaiah is an accomplished academician with a diverse research background in medical neuroscience, focusing on brain tumors and neurodegeneration, as well as cell/molecular neurochemistry, including neural stem cells and hydrolases. She holds an MSc in Biochemistry from Central College (1996) and a PhD in Biochemistry from Bangalore University and NIMHANS (2005). Prabha also completed a visiting fellowship at NCBS in 2006 and a postdoctoral fellowship at MCBL, IISc from 2007 to 2008. With over 24 years of research experience, including a PhD and postdoctoral training, she has spent 15 years in academia, with 7 years as an Assistant Professor and currently serving as an Associate Professor since 2017. She has delivered 8 invited talks and received around 30 invitations to speak abroad, published 20 research papers (18 as the first author), and served as an invited reviewer for journals like *Journal of Neurochemistry* and *Cancer Biomarkers*. Prabha is also a life member of several academic organizations, including IAN and SNCI India, and is an editorial member of three journals. Her contributions have earned her several prestigious awards, including the Bharat Shiksha Gaurava Puraskar, the Excellence for Best Educationist Award in 2022, and the Eminent Educationist of India Award by KTK Foundation, New Delhi, in November 2022. She also received the NPTEL Domain Star award in Biotechnology-Biosciences in 2022, earning six silver medals and an Elite certificate, and was recognized with the Women Researcher Award at the International Scientist Awards on Engineering, Science, and Medicine in November 2022.